Home Infusion Therapy: IV Medications and Administration at Home

Home infusion therapy encompasses the intravenous, subcutaneous, or epidural delivery of medications, nutrition, and biological agents in a residential setting rather than a hospital or clinic. The practice spans a broad clinical spectrum — from antibiotics and chemotherapy agents to total parenteral nutrition and immunoglobulin infusions — and involves a coordinated system of prescribers, pharmacists, nurses, and patients or caregivers. Understanding the regulatory framework, clinical mechanics, and classification boundaries of home infusion therapy is essential for patients, family members, healthcare providers, and policymakers navigating this complex segment of post-acute home care.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps (Non-Advisory)
• Reference Table or Matrix
• References

Definition and Scope

Home infusion therapy refers to the preparation, dispensing, and clinical management of drugs and nutrients delivered parenterally — that is, outside the gastrointestinal tract — in a patient's place of residence. The National Home Infusion Association (NHIA) defines the service as requiring three integrated components: a state-licensed pharmacy that compounds and dispenses the infusible product, nursing services to administer or train patients, and ongoing clinical monitoring.

Regulatory authority over home infusion spans multiple federal and state bodies. The U.S. Food and Drug Administration (FDA) governs drug compounding standards for infusion pharmacies under 21 U.S.C. § 353b and the Drug Quality and Security Act (DQSA) of 2013. The Centers for Medicare & Medicaid Services (CMS) establishes coverage criteria under the Medicare home health benefit (42 C.F.R. Part 484) and the separate Medicare Part B and Part D drug benefit structures. State boards of pharmacy impose additional compounding and dispensing requirements that vary by jurisdiction.

The scope of conditions treated through home infusion is extensive. Clinical indications include serious bacterial infections requiring intravenous antibiotics (e.g., vancomycin, cefazolin), primary immunodeficiency diseases requiring subcutaneous or intravenous immunoglobulin (IVIG/SCIG), malabsorptive conditions requiring total parenteral nutrition (TPN), cancer treated with systemic chemotherapy, chronic pain managed via epidural or intrathecal drug delivery, and congestive heart failure requiring inotropic support. The home-infusion-therapy category thus sits at the intersection of pharmacy practice, nursing, and durable medical equipment — a convergence that creates layered licensure obligations.

Core Mechanics or Structure

The home infusion delivery model involves five discrete operational phases:

1. Physician Order and Plan of Care
A licensed prescriber issues an order specifying the drug, dose, route, frequency, and duration. Under plan-of-care-home-health requirements, CMS mandates that a physician certify and periodically recertify the plan for Medicare-covered episodes.

2. Pharmacy Compounding and Dispensing
A home infusion pharmacy — which may be an outsourcing facility registered under FDA's 503B framework or a traditional 503A compounder — prepares the sterile product under United States Pharmacopeia (USP) Chapter <797> standards. USP <797> specifies beyond-use dating, sterility testing intervals, and cleanroom environmental monitoring requirements. Failures in this step have historically caused sepsis outbreaks; an FDA enforcement action in 2012 against the New England Compounding Center (NECC) following a fungal meningitis outbreak that killed 64 patients (CDC, 2013) led directly to the DQSA.

3. Equipment and Supply Delivery
Infusion pumps, administration sets, catheters, and ancillary supplies are delivered to the home. Pumps used in home settings — including ambulatory elastomeric infusers and electronic volumetric pumps — must comply with FDA device regulations under 21 C.F.R. Part 880, as amended effective February 2, 2026. Covered entities should ensure that device procurement, labeling, and post-market surveillance practices reflect the requirements of the 2026 amendment, which became operative on that date.

4. Nursing Assessment and Administration
A registered nurse conducts an initial home visit to verify venous access integrity, train the patient or caregiver on self-administration technique, assess the home environment for safety, and document baseline clinical parameters. Subsequent visits may be daily, intermittent, or replaced by patient self-administration once competency is established. Skilled nursing at home functions as the clinical backbone of this phase.

5. Monitoring and Follow-Up
Pharmacists and nurses conduct ongoing clinical monitoring — including laboratory draws for drug levels, renal function, and electrolytes — and report findings to the prescriber. Remote patient monitoring platforms are increasingly used to transmit vital signs and symptom data between nursing visits.

Causal Relationships or Drivers

Several structural forces drive the growth and persistence of home infusion as a care modality:

Hospital-Acquired Infection Risk Reduction: Catheter-associated bloodstream infections (CABSIs) and hospital-acquired infections (HAIs) represent documented harms of inpatient care. The CDC's National Healthcare Safety Network tracks CABSI rates in acute care settings, and removing patients from that environment eliminates a portion of that exposure — though it transfers infection risk management to a less controlled setting.

Cost Differential: The cost of inpatient IV antibiotic therapy consistently exceeds the cost of equivalent home-based therapy when controlling for drug and nursing visit costs. The Agency for Healthcare Research and Quality (AHRQ) has documented that hospital stays for conditions amenable to outpatient IV therapy represent avoidable expenditures under value-based payment models.

Regulatory Coverage Incentives: Medicare's home health benefit covers skilled nursing visits associated with infusion therapy, but coverage of the drug itself depends on whether it falls under Part A (post-acute), Part B (specific drugs administered by a provider), or Part D (self-administered). This fragmented structure creates both access barriers and financial incentives that influence prescribing and discharge decisions. Medicare home health benefit documentation details this tripartite structure.

Technological Enablement: Advances in vascular access — peripherally inserted central catheters (PICCs), implanted ports, and midline catheters — have made long-duration IV therapy feasible outside hospital settings. Ambulatory infusion pumps weighing under 500 grams allow patients to receive continuous infusions while remaining mobile.

Classification Boundaries

Home infusion therapy is not a single modality but a family of distinct services with different regulatory, clinical, and reimbursement profiles:

Note that enteral nutrition — delivered via nasogastric or gastrostomy tube — is classified separately under durable medical equipment rules (home-medical-equipment-dme) rather than home infusion, despite frequent conflation in lay usage.

Tradeoffs and Tensions

Compounding Safety vs. Access: Stricter USP <797> enforcement and FDA oversight of outsourcing facilities improve sterility assurance but increase pharmacy operating costs and may reduce the number of compliant compounders available in rural markets. This creates geographic disparities in access.

Autonomy vs. Clinical Oversight: Patient self-administration reduces nursing visit frequency and cost but increases the risk of technique errors, line infections, and missed adverse drug reactions. The appropriate balance depends on patient literacy, caregiver support, drug risk profile, and access to emergency services — factors that are assessed individually but not standardized nationally.

Reimbursement Fragmentation: The split between Medicare Parts A, B, and D means that a single home infusion episode may be covered under incompatible benefit structures depending on patient discharge status, drug classification, and who administers the infusion. This fragmentation was partially addressed by the 21st Century Cures Act of 2016, which directed CMS to create a home infusion therapy benefit under Medicare Part B effective January 1, 2021 — but the benefit covers nursing visits only, not the drug itself, leaving the pharmaceutical component under Part B or Part D depending on drug type (CMS, Final Rule CY 2021).

Infection Control in Uncontrolled Environments: Infection control in home care presents inherent challenges. Hospitals maintain regulated environmental conditions; homes do not. The absence of standardized hand hygiene infrastructure, sharps disposal protocols, and refrigeration monitoring creates variable sterility maintenance that cannot be fully offset by patient education alone.

Common Misconceptions

Misconception: Home infusion is only for antibiotics.
Home infusion encompasses 15 or more distinct drug categories including immunoglobulins, biologics, chemotherapy, TPN, and cardiovascular agents. Anti-infectives represent one segment, not the totality.

Misconception: Any IV medication can be administered at home.
Regulatory, pharmacokinetic, and safety constraints exclude certain drug classes from home use. Drugs requiring continuous cardiac monitoring (certain antiarrhythmics), agents with narrow therapeutic indices requiring real-time laboratory adjustment, and hazardous drugs requiring controlled-environment handling under OSHA's hazardous drug standards (29 C.F.R. § 1910.1200 and USP Chapter <800>) may not be appropriate for home settings regardless of patient preference.

Misconception: Home infusion pharmacies operate under the same rules as retail pharmacies.
Home infusion pharmacies must comply with USP <797> sterile compounding standards, state board sterile compounding permits (distinct from standard pharmacy licensure in most states), FDA outsourcing facility registration if they compound in bulk, and ACHC or URAC accreditation standards — a substantially more complex regulatory stack than traditional dispensing pharmacies.

Misconception: Medicare covers all home infusion drugs under the home health benefit.
CMS's home health benefit (Part A) covers skilled nursing visits associated with infusion but does not cover the drugs themselves under that benefit. Drug coverage depends on Part B or Part D eligibility rules. TPN, for example, is covered under Part B as a prosthetic device benefit, while IVIG has its own Part B coverage category.

Checklist or Steps (Non-Advisory)

The following sequence describes the standard phases of a home infusion therapy episode as documented in clinical literature and CMS guidance. This is a descriptive reference, not a care protocol.

Phase 1 — Clinical Authorization
- [ ] Prescriber issues a written order specifying drug, dose, route, frequency, and anticipated duration
- [ ] Diagnosis code(s) documented and supporting the medical necessity of parenteral route
- [ ] Patient eligibility for relevant Medicare/Medicaid benefit verified (see medicaid-home-care-coverage)
- [ ] Prior authorization obtained from payer if required

Phase 2 — Pharmacy Intake and Dispensing
- [ ] Home infusion pharmacy verifies prescription, allergy history, and current medication list
- [ ] Compounding performed under USP <797> sterile conditions
- [ ] Beyond-use date assigned per USP <797> risk-level classification
- [ ] Infusion supplies and pump selected and programmed per order

Phase 3 — Vascular Access
- [ ] Appropriate catheter type selected (peripheral IV, midline, PICC, port, or tunneled catheter)
- [ ] Catheter placed by qualified clinician with confirmation of tip position where required
- [ ] Dressing and securement applied per INS (Infusion Nurses Society) standards

Phase 4 — Patient/Caregiver Training
- [ ] Training on aseptic technique documented
- [ ] Pump operation and alarm response reviewed
- [ ] Signs of adverse reactions and line complications identified to patient
- [ ] Emergency contact chain established

Phase 5 — Ongoing Monitoring
- [ ] Laboratory monitoring schedule established (drug levels, CBC, metabolic panel as indicated)
- [ ] Nursing visit frequency defined in plan of care
- [ ] Pharmacist clinical review documented at defined intervals
- [ ] Adverse event reporting pathway established per agency policy

Reference Table or Matrix

Home Infusion Drug Categories: Regulatory and Coverage Reference

INS = Infusion Nurses Society; IT = intrathecal; PICC = peripherally inserted central catheter; CIDP = chronic inflammatory demyelinating polyneuropathy.

References

• U.S. Food and Drug Administration — Drug Quality and Security Act (DQSA)
• U.S. FDA — 503B Outsourcing Facility Guidance
• Electronic Code of Federal Regulations — 42 C.F.R. Part 484 (Home Health Agencies)
• Centers for Medicare & Medicaid Services — Home Infusion Therapy Services Payment (CY 2021)
• CDC — New England Compounding Center Fungal Meningitis Outbreak (2013)
• United States Pharmacopeia — USP Chapter <797> Pharmaceutical Compounding — Sterile Preparations
• United States Pharmacopeia — USP Chapter <800> Hazardous Drugs — Handling in Healthcare Settings
• OSHA — Hazardous Drugs in Healthcare Settings (29 C.F.R. § 1910.1200)
• Infusion Nurses Society — Infusion Therapy Standards of Practice
• [Agency for Healthcare Research and Quality (AHRQ) — Hospital-Acquired Conditions](https